Abstract 1279
Background
The newly created Department of Oncology Nurse Coordinators, in this case the Digestive Oncology department, ONCDOD, at the Jules Bordet Institute, allows patients, mainly the newly diagnosed, to early personalized medicine. The aim is to orient the patients to all the services available and implicated to his/her care; to explain the treatment, procedures for therapies and answer questions; to be present for the patient and his family so as to create a climate of confidence, comfort and security.
Methods
60 newly diagnosed digestive patients were followed by the Nurse Coordinator in the year 2018. The necessary care requirements for this group of patients were identified, recorded and analysed in collaboration with the multidisciplinary team. With the help of an exhaustive data on the patient, all the Oncology Nurse Coordinator’s activities were reported in a unique, accessible electronic patient’s file.
Results
Thanks to knowledge of the patient’s medical situation, but also to his psychological and socioeconomic environment, the interventions of the Oncology Nurse Coordinator allowed a more fluid path of diagnosis and treatment, rapid and efficient care of treatment side effects, avoid unnecessary hospitalization and ensure more comfort and security for the patient.
Conclusions
The daily follow-up of newly diagnosed digestive patients, allowed a more effective taking care of patients from the diagnosis. The patients showed confidence and serenity knowing that they can call one single person, anytime, in the hospital for all their questions and needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fouad Awada.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3190 - GI101, a novel triple-targeting bispecific CD80-IgG4-IL2variant fusion protein, elicits synergistic anti-tumor effects in preclinical models
Presenter: Jae Chan Park
Session: Poster Display session 3
Resources:
Abstract
4062 - Phase 1b, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumors
Presenter: Julius Strauss
Session: Poster Display session 3
Resources:
Abstract
5777 - THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS)
Presenter: Marcos Milla
Session: Poster Display session 3
Resources:
Abstract
5047 - A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells
Presenter: Alessandra Curioni
Session: Poster Display session 3
Resources:
Abstract
1679 - HPV16 E6-specific TCR-T armored with checkpoint blockade in the treatment of cervical cancer
Presenter: Paul Bryson
Session: Poster Display session 3
Resources:
Abstract
1133 - the Mutant Neoantigen Specific T Cell Is a Personalized Immunotherapy in Refractory Solid Tumor
Presenter: Qi Song
Session: Poster Display session 3
Resources:
Abstract
3338 - NY-ESO-1 and LAGE1A –an emerging target for cell therapies in solid tumours
Presenter: Ioanna Eleftheriadou
Session: Poster Display session 3
Resources:
Abstract
3089 - Targeting myeloid-derived suppressor cells and T cells: combination treatment with MTL-CEBPA and PD-1 antibody in a mouse syngeneic CT26 model
Presenter: Mikael Sodergren
Session: Poster Display session 3
Resources:
Abstract
5991 - Master Checkpoint Cbl-b Inhibition: Anti-tumor Efficacy in a Murine Colorectal Cancer Model Following siRNA-based Cell Therapy
Presenter: Kathrin Thell
Session: Poster Display session 3
Resources:
Abstract
5007 - Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
Presenter: Miren Zuazo
Session: Poster Display session 3
Resources:
Abstract